ABL Bio (298380) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, ABL Bio (298380) reported revenue of 79.3 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202579.3 billion KRW-40.4 billion KRW-37.9 billion KRW[source]
202433.4 billion KRW-59.4 billion KRW-55.5 billion KRW[source]
202365.5 billion KRW-2.6 billion KRW-2.6 billion KRW[source]
202267.3 billion KRW908 million KRW3.2 billion KRW[source]
20215.3 billion KRW-52.3 billion KRW-43.6 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025281.9 billion KRW124.1 billion KRW157.8 billion KRW[source]
2024233.0 billion KRW65.1 billion KRW167.9 billion KRW[source]
2023161.2 billion KRW86.5 billion KRW74.8 billion KRW[source]
2022143.1 billion KRW72.9 billion KRW70.1 billion KRW[source]
202165.5 billion KRW9.5 billion KRW56.0 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice